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Background: Whole-genome sequencing studies have recently shown that osteosarcomas (OSs) display high rates of
structural variation, i.e. they contain many somatic mutations and copy number alterations. TP53 and RB1 show recurrent
somatic alterations in concordant studies, suggesting that they could be key players in bone oncogenesis.
Patients and methods: we carried out whole-genome sequencing of DNA from seven high-grade OS samples
matched with normal tissue from the same patients.
Results: We conﬁrmed the presence of genetic alterations of the TP53 (including novel unreported mutations) and RB1
genes. Most interestingly, we identiﬁed a total of 84 point mutations and 4 deletions related to 82 different genes in OS
samples, of which only 15 have been previously reported. Interestingly, the number of mutated genes (ranging from 4 to
8) was lower in TP53mut cases compared with TP53wt cases (ranging from 14 to 45). This was also true for the mutated
RB1 case. We also observed that a dedifferentiated OS harboringMDM2 ampliﬁcation did not carry any other mutations.
Conclusion: This study suggests that bone oncogenesis driven by TP53 or RB1 mutations occurs on a background of
relative genetic stability and that the dedifferentiated OS subtype represents a clinico-pathological entity with distinct
oncogenic mechanisms and thus requires different therapeutic management.
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introduction
Osteosarcoma (OS) is the most common primary malignant
type of bone cancer and has a worldwide incidence of approxi-
mately one to three cases per million annual, with a higher in-
cidence in adolescents (0.8–1.1/100 000/year for ages 15–19).
The 2013 World Health organization (WHO) classiﬁcation
distinguishes different OS subtypes on the basis of both their
location in relation to the bone cortex (central or surface OS)
and their grade (low, high or intermediate [1]. High-grade OS
are themselves divided into different subtypes: conventional
(the most common one, 90% of all OS), telangiectasic and
small-cell OS (respectively 4% and 1.5% of all OS) and the ded-
ifferentiated OS [1]. This latter corresponds to the transform-
ation of a low-grade OS into an OS of higher grade. Low-grade
and its dedifferentiated form are deﬁned by a simple genomic
proﬁle with episomal ring neochromosomes containing high-
level ampliﬁcation of MDM2 (murine double-minute type 2)
and CDK4 (cyclin-dependent kinase 4) [2, 3]. Microscopically,
low-grade OS is characterized by a paucicellular stroma of fusi-
form cells harboring minor cytonuclear atypia and well-differ-
entiated bone trabeculae [1]. Dedifferentiated OS is most often
composed of cells with larger atypia and mitosis than its low-
grade counterparts and by the presence of an immature
osteoid production. Tumor necrosis may also be present [1, 3].
In the dedifferentiated form, areas of low- and high-grade tumor
may or may not coexist. When the low- grade contingent is not
present on biopsy specimens or surgical resection, dedifferentiated
OS could be misdiagnosed with conventional OS. The diagnosis
of the dedifferentiated form is made on the molecular signature
(ampliﬁcation of MDM2 gene) [3]. Conversely, the other high-
grade OS are complex genomic sarcomas with multiple numer-
ical and structural chromosomal aberrations that present no
speciﬁc diagnostic signature [1].
Several heritable genetic syndromes predispose to OS: Li–
Fraumeni syndrome or heritable retinoblastomas are related to
germ-line mutations in the TP53 and RB1 tumor suppressor
genes, respectively [4, 5]. The genetic instability of OS results in
recurrent ampliﬁcation and DNA copy number gains at distinct
chromosomal regions [1]. Recently, whole-genome sequencing
studies have shown that among pediatric cancers, OS have the
highest rate of structural variation, i.e. they contain many
somatic mutations and copy number alterations [6, 7]. A few re-
current single-nucleotide variations or recurrent point muta-
tions have been found [7]. These studies have conﬁrmed the
major roles of recurrent alterations of the TP53 and RB1 genes
in OS (80%–90% and 10%–39%, respectively). The majority of
TP53 mutations are rearrangements with breakpoints conﬁned
to the ﬁrst intron of the gene [7, 8]. This is therefore a particu-
larly unstable region that is sensitive to structural variations that
occur before inactivation of TP53 and that are likely to be the
initiating factors in OS development [7]. Another recent study
has also conﬁrmed the importance and prevalence of TP53 and
RB1 inactivation by genomic events, which either affect the
TP53 or RB1 genes directly or alter TP53/RB1-interacting genes.
In this study, the authors also reported that 75% of somatic
events lead to the direct or indirect inactivation of TP53 [6].
Besides TP53 and RB1, the ATRX, DLG2, RUNX2 and PTEN
genes have been shown to incur recurrent somatic alterations in
30%, 30%, 52%, 18–55% and 44% of OS, respectively [7]. The
ATRX gene is known to regulate telomere maintenance and
could therefore have an important role in OS development [9].
Alterations in CDC27, a gene controlling the cell cycle, and the
MUC4 and EI24 genes known to encode tumor suppressors,
were also recently reported [10]. In addition, genome sequen-
cing data have shown that the novel genetic mechanism referred
to as chromothripsis (Greek; chromos for chromosome, thripsis
for shattered into pieces) is involved in 33% of primary OS com-
pared with 2%–3% of cancers overall [11]. Chromothripsis
appears to be a cataclysmic event in which a single or in some
cases, a few chromosomes are broken into many pieces and then
stitched back together [11, 12]. Chromothripsis may lead to
the generation of ampliﬁcations of one or more genes or to the
deletion of one or more tumor suppressor genes. It may also
explain the sudden onset of OSs and the complexity and hetero-
geneity of the OS genome [1, 11, 12]. In a recent study, exome
proﬁles in one patient showed almost 3000 somatic single-
nucleotide variants (SNVs) and small indels and more than
2000 copy number variants in different chromosomes, reinfor-
cing the major role of this phenomenon [10]. Kataegis (a
pattern of localized hypermutation in a SNV) has also been
reported in OS, although the study of Perry et al. [6] reported a
higher prevalence (85% of OS) than that reported by Chen et al.
[7] (50% of OS). However, this process is certainly less import-
ant because it does not occur in the most recurrently mutated
genes [7].
To further reﬁne the landscape of somatic mutations in pedi-
atric OS, we carried out exome sequencing of DNA from seven
OS samples matched with normal tissues from the same patients
(Table 1). Three important ﬁndings arise from this work. Our
results conﬁrm: (i) the heterogeneity of genetic alterations in
conventional high-grade OS by providing new unreported
mutations, (ii) the dominant role of TP53 and RB1 gene inacti-
vation in the development of OS, and (iii) that dedifferentiated
OS is a separate entity with a different pathophysiology from that
of conventional high-grade OS.
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Table 1. Mutated genes detected by whole-exome sequencing
Patient Gene Chr Position REF ALT dbSNP Effect Type
1 TP53a chr17 7 578 275 G A None STOP_GAINED Mut
1 PSD4a chr2 113 942 572 T G None NON_SYNONYMOUS_CODING Mut
1 CLNS1A chr11 77 333 719 C A None SPLICE_SITE_ACCEPTOR Mut
1 SPTB chr14 65 253 678 C T None NON_SYNONYMOUS_CODING Mut
1 TSC2a chr16 2 138 087 G A None NON_SYNONYMOUS_CODING Mut
1 CHL1 chr3 425 527 G T None NON_SYNONYMOUS_CODING Mut
2 RB1a chr13 49 039 501 C A None STOP_GAINED Mut
2 GPRC6Aa chr6 117 121 780 A T None NON_SYNONYMOUS_CODING Mut
2 C1orf174 chr1 3 807 588 T G None NON_SYNONYMOUS_CODING Mut
2 LTF chr3 46 506 382 C T None UTR_5_PRIME Mut
2 POLD2 chr7 44 154 485 C T None NON_SYNONYMOUS_CODING Mut
2 CXorf22 chrX 35 969 379 G C None NON_SYNONYMOUS_CODING Mut
3 TP53a chr17 7 578 455 C A None NON_SYNONYMOUS_CODING Mut
3 TP53a chr17 7 578 451 ATGG A None CODON_CHANGE_PLUS_CODON_DELETION Indel
3 TP53a chr17 7 578 434 ACTGCTTGTAGATGG A None FRAME_SHIFT Indel
3 ABCA13a chr7 48 452 019 C A None NON_SYNONYMOUS_CODING Mut
3 RP1L1a chr8 10 466 225 C G None NON_SYNONYMOUS_CODING Mut
3 OR8I2 chr11 55 861 061 C T None NON_SYNONYMOUS_CODING Mut
3 CACNA1C chr12 2 229 523 T C None NON_SYNONYMOUS_CODING Mut
3 STYK1 chr12 10 787 262 A C None UTR_5_PRIME Mut
3 WFDC9 chr20 44 236 751 A G None STOP_LOST Mut
3 NOBOX chr7 144 094 557 G A None NON_SYNONYMOUS_CODING Mut
3 PIWIL2 chr8 22 137 017 G A None NON_SYNONYMOUS_CODING Mut
5 CR1a chr1 207 751 260 A G rs202070239 NON_SYNONYMOUS_CODING Mut
5 CR1a chr1 207 751 252 T C rs200111726 NON_SYNONYMOUS_CODING Mut
5 LRRC16Ba chr14 24 537 870 A C None NON_SYNONYMOUS_CODING Mut
5 SYNE2a chr14 64 688 390 C T rs35700578 NON_SYNONYMOUS_CODING Mut
5 SALL1a chr16 51 175 831 G A None NON_SYNONYMOUS_CODING Mut
5 DNAH6a chr2 84 848 403 G A rs185981876 NON_SYNONYMOUS_CODING Mut
5 ADAMTS16a chr5 5 319 934 A G rs58353460 UTR_3_PRIME Mut
5 C1orf189 chr1 154 178 828 CTCT C None UTR_5_PRIME Indel
5 EPS8L3 chr1 110 292 938 CG C rs148530481 UTR_3_PRIME Indel
5 NAV2 chr11 20 075 708 A G None NON_SYNONYMOUS_CODING Mut
5 TENM4 chr11 78 381 189 C A None NON_SYNONYMOUS_CODING Mut
5 KRT72 chr12 52 984 733 G C rs34769047 NON_SYNONYMOUS_CODING Mut
5 KRT80 chr12 52 574 730 G A rs141379526 NON_SYNONYMOUS_CODING Mut
5 ARHGAP5 chr14 32 561 778 C T rs115598823 NON_SYNONYMOUS_CODING Mut
5 COQ6 chr14 74 428 000 A T rs2074930 NON_SYNONYMOUS_CODING Mut
5 DCAF5 chr14 69 521 338 C A rs116182003 NON_SYNONYMOUS_CODING Mut
5 G2E3 chr14 31 067 748 G A rs17096934 NON_SYNONYMOUS_CODING Mut
5 GZMH chr14 25 075 810 T A rs115493987 STOP_LOST Mut
5 MLH3 chr14 75 514 200 T C rs28756988 NON_SYNONYMOUS_CODING Mut
5 PAPLN chr14 73 721 300 C T rs17126354 NON_SYNONYMOUS_CODING Mut
5 PLEKHH1 chr14 68 042 573 C A rs186582399 NON_SYNONYMOUS_CODING Mut
5 RBM23 chr14 23 374 568 C T rs34246954 NON_SYNONYMOUS_CODING Mut
5 RNASE10 chr14 20 978 738 G T rs74037153 NON_SYNONYMOUS_CODING Mut
5 RNASE13 chr14 21 501 843 G A rs116165621 UTR_3_PRIME Mut
5 TSHR chr14 81 422 169 A G rs147137913 NON_SYNONYMOUS_CODING Mut
5 COQ9 chr16 57 493 629 G C rs61730662 NON_SYNONYMOUS_CODING Mut
5 GP2 chr16 20 330 955 G T None NON_SYNONYMOUS_CODING Mut
5 NUBP2 chr16 1 838 050 A G rs57822546 NON_SYNONYMOUS_CODING Mut
5 CHST8 chr19 34 263 855 G A None NON_SYNONYMOUS_CODING Mut
5 DHDH chr19 49 436 982 G C rs10401800 NON_SYNONYMOUS_CODING Mut
5 TMEM221 chr19 17 556 074 C T None NON_SYNONYMOUS_CODING Mut
5 PLB1 chr2 28 849 317 G A None STOP_GAINED Mut
5 SH3YL1 chr2 231 067 G C None NON_SYNONYMOUS_CODING Mut
5 SCP2D1 chr20 18 794 656 T A None NON_SYNONYMOUS_CODING Mut
5 MIRLET7BHG chr22 46 505 806 C G rs12159905 EXON Mut
5 PKDREJ chr22 46 656 242 A G rs34798212 NON_SYNONYMOUS_CODING Mut
5 TMPRSS6 chr22 37 464 655 C G rs80252000 SPLICE_SITE_DONOR Mut
5 ATR chr3 142 272 671 T C None NON_SYNONYMOUS_CODING Mut
5 MANBA chr4 103 579 032 G A rs370002189 NON_SYNONYMOUS_CODING Mut
5 MIR6082 chr4 172 107 395 C T rs28570267 EXON Mut
5 CEP120 chr5 122 714 044 T C rs61744334 NON_SYNONYMOUS_CODING Mut
5 TRDN chr6 123 714 778 C T rs35047281 NON_SYNONYMOUS_CODING Mut
5 CTNNAL1 chr9 111 735 031 G C rs16913734 NON_SYNONYMOUS_CODING Mut
5 GLDC chr9 6 606 634 C T rs28617412 NON_SYNONYMOUS_CODING Mut
5 ESX1 chrX 103 495 445 G C None NON_SYNONYMOUS_CODING Mut
6 DUSP27a chr1 167 096 814 G T None NON_SYNONYMOUS_CODING Mut
6 VPS13Da chr1 12 336 850 G C None NON_SYNONYMOUS_CODING Mut
6 EFCAB6a chr22 44 022 541 A G None NON_SYNONYMOUS_CODING Mut
6 GCSAML chr1 247 726 894 A G None NON_SYNONYMOUS_CODING Mut
6 SYNC chr1 33 161 551 C G None NON_SYNONYMOUS_CODING Mut
6 OR9Q1 chr11 57 947 475 T G None NON_SYNONYMOUS_CODING Mut
6 TRPC4 chr13 38 320 482 C A None NON_SYNONYMOUS_CODING Mut
6 PFAS chr17 8 170 715 C G None NON_SYNONYMOUS_CODING Mut
6 CATSPERD chr19 5 757 865 C A None NON_SYNONYMOUS_CODING Mut
6 DLL1 chr6 170 594 743 C T None NON_SYNONYMOUS_CODING Mut
6 DDHD2 chr8 38 109 710 C G None NON_SYNONYMOUS_CODING Mut
6 MCMDC2 chr8 67 808 447 A C None NON_SYNONYMOUS_CODING Mut
6 TAF1L chr9 32 632 563 C A None NON_SYNONYMOUS_CODING Mut
6 NRK chrX 105 189 927 A C None NON_SYNONYMOUS_CODING Mut
7 TP53a chr17 7 577 018 C T None SPLICE_SITE_DONOR Mut
7 PLCB2 chr15 40 590 865 C T None NON_SYNONYMOUS_CODING Mut
7 HID1 chr17 72 956 123 C T None NON_SYNONYMOUS_CODING Mut
7 KLB chr4 39 436 255 T A None NON_SYNONYMOUS_CODING Mut
7 GRIA1 chr5 153 181 955 G A None NON_SYNONYMOUS_CODING Mut
aIn dark gray genes previously described in Perry et al. [6] and in light gray by Chen et al. [7].
fragments (200–300 bp). Extracted DNAwas ampliﬁed by ligation-mediated
PCR (LM-PCR), then puriﬁed and hybridized to the Roche NimbleGen
SeqCap EZ Exome probe. Nonhybridized fragments were washed out. Both
noncaptured and captured LM-PCR products were subjected to quantitative
PCR to estimate the magnitude of enrichment. Each captured library was
then loaded on to a Hiseq2000 (Illumina) platform. High-throughput se-
quencing for each captured library was carried out independently to ensure
that each sample met the desired average fold-coverage of 50×. Raw image
ﬁles were processed by Illumina base calling Software 1.7 for base calling
with default parameters and the sequences of each individual were generated
as 91-bp paired-end reads.
bioinformatical analysis
First, the adapter sequences in the raw data, generated from the Illumina
pipeline, were removed, and low-quality reads that had too many Ns or low
base quality were discarded. This step produced the ‘clean data’. Second, the
Burrows-Wheeler Aligner [BWA mem (0.7.9a-r786)] was used to carry out
the alignment against the human reference genome Hg19. Samples were
then realigned and recalibrated with GATK (v3.0). HaplotypeCaller was
used to call variants using standard options and a bed of exome region. The
annotation was performed with SnpEff (v3.6c) against Hg19 with the option
‘cancer’. For SNP and indels, we applied the following ﬁlters: the mutation
must have not existed in cell line samples (even one read) and, for control
patient samples, the mutation must have had a minimum allele frequency
(MAF) below: 5% for control patient 1, 15% for control patient 2, 5% for
control patient 3, 0% for control patient 4, 40% for control patient 5, 10% for
control patient 6 and 10% for control patient 7. These percentages corres-
pond to the putative contamination of remaining cancer cells. Only muta-
tions with a depth higher than 20 were considered. Moreover, we selected
mutations and indels in tumor samples with MAF >30% and MAF >20% re-
spectively. Finally, for each mutation, the tumor sample MAF had to be 2.5
times higher than the MAF of the matched control sample and, for each
A C
B D
Figure 1. (A) Histological appearance of an intramedullary (central) dedifferentiated osteosarcoma (H&E). (B) Magniﬁcation of rectangle shown in
A. Necrosis area (open arrow) in a dedifferentiated osteosarcoma and immature neoplastic osteoid (black arrow) (H&E). (C) Spindle cells with moderate
nuclear atypia, mitosis and immature neoplastic osteoid production (H&E). (D) MDM2 nuclear immunostaining in a dedifferentiated osteosarcoma.
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patients and methods
OS samples and cell lines
Seven OS samples coming from initial biopsy and seven matched control DNA 
samples were collected from patients registered at the ‘CRB cancer des Hôpitaux 
de Toulouse; BB-0033-00014’ collection. This study had approval from institu-
tional and national ethics committees. Thawed samples were obtained after 
informed consent in accordance with the Declaration of Helsinki and after au-
thorization of the French ministry of higher education and research (declaration 
DC 2009-989; DC-2011-1388; transfer agreement AC-2008-820; AC-2011-130). 
Clinical and biological annotations were consistent with CNIL (Comité National 
Informatique et Libertés) guidelines. Samples were stored in the certiﬁed 
biobank of the Hôpitaux de Toulouse. Control samples corresponded to tissues 
taken from surgical resection that were obtained after chemotherapy treatment. 
The percentage of cancer cells remaining in control samples was evaluated by 
morphological analysis after decalciﬁcation and hematoxylin–eosin staining.
Six patients had high-grade conventional OS. Among them, ﬁve were 
good responders with a percentage of residual cells lower than 10% and are 
alive. One was a poor responder with 27% residual cells (patient 5). He died 
from lung metastases.
Patient 4 presented with intramedullary (central) dedifferentiated OS 
(Figure 1A–C) with MDM2 overexpression (Figure 1D) and ampliﬁcation 
(conﬁrmed by qPCR). Due to a dedifferentiated component in the diagnostic 
biopsy, he received neoadjuvant chemotherapy. He was a good responder 
according to the surgical resection analysis and he is still alive (supplemen-
tary Table S1, available at Annals of Oncology online).
Two osteoblastic cell lines (TF13 and TF15) were also used as controls 
[13]. DNA sample integrity was evaluated by agarose gel electrophoresis.
exome sequencing
Three micrograms of qualiﬁed genomic DNA were randomly fragmented by 
Covaris and then adapters were ligated to both ends of the resulting
and the entire or a portion of the DNA binding domain but they
have lost their oligomerization and C-Terminal regulatory
domains (Figure 2). We can postulate that these mutations lead
to the degradation of TP53 mRNA by the nonsense-mediated
mRNA decay or that truncated TP53 act as dominant negative
mutants on the TP53 wild type as previously described [14]. We
also detected a STOP gained mutation (aa829) in the retino-
blastoma 1 (RB1) gene in one case. This gene is also known to
be frequently mutated in OS [1]. In their recent study, Chen
et al. investigated recurrent somatic structural variations in pedi-
atric OS and identiﬁed 2057 point mutations in 1707 genes [7].
In addition to TP53 and RB1, they observed recurrent somatic
alterations of the ATRX and DLG2 genes, with the ATRX gene
being one of the most frequently mutated genes. In our cohort,
however, we did not observe any ATRX mutations. This ﬁnding
may be explained by the size of our series but also by geograph-
ical variation since we would expect to detect this alteration in at
least two of our cases. Alterations in CDC27, a gene controlling
the cell cycle, and the MUC4 and EI24 genes, have also been re-
cently reported in a single case of OS [10]. We did not ﬁnd any
alteration in these genes in our patients.
However, among the 82 mutated genes described in our
study, 15 were also reported by Chen et al., suggesting that
these genes are recurrently mutated in OS [7]. Mutations in the
TSC2 gene are our only ﬁnding in common with the study by
Perry et al. [6] Among the 16 genes described above, some are
involved in cell cycle regulation, tumor cell division, transcrip-
tion and proliferation (TP53, RB1, LRRC16B, PSD4, ADAMS16,
SALL1, EFCAB6), and others are involved in cytoskeletal integ-
rity, cytoplasmic trafﬁcking and energy metabolism (SYNE2,
DNAH6, VPS13D, DUSP27). The CR1 gene found mutated in
our study seems to have a predominant role in the immune re-
sponse and TSC2 is involved in the PI3K/mTOR pathway [6]
making this gene/pathway a potential therapeutic target.
However, it should be mentioned that all the point mutations
we observed in CR1, LRRC16B, SYNE2, SALL1, PSD4, GPRD6A,
ABCA13, RP1L1, DUSP27, VPS13D, EFCAB6 and TSC2 are new
mutations, distinct from those previously reported [6, 7]. These
ﬁndings emphasize the extreme genomic instability of OS and
support the hypothesis that the processes of chromothripsis,
deﬁned by tens to hundreds of genomic rearrangements occur-
ring in one-off cellular crisis and which have already been
described to have a frequency of 50% in OS [6, 7], is indeed a
frequent event in this pathology.
Among the three patients found to have no mutations in the
TP53 and RB1 genes, one (patient 4) was a dedifferentiated OS.
TP53
protein 1–42
Patient 3
Non synonymous mutation (aa159)
Deletion aa159–160
Deletion aa161–165
Patient 1
STOP gain mutation
(aa192)
Patient 7
Mutation on donor
splice site (aa307)
Transactivation
domain
SH3 DNA-binding domain
63–97 98–292 324–355
Oligomerization
domain
C-terminal
regulatory
domain
363–393
Figure 2. TP53 mutations observed in three patients.
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indel, the tumor sample MAF had to be two times higher than the MAF of 
the matched control sample.
results
We identiﬁed a total of 84 point mutations and 4 deletions 
related to 82 different genes from our OS samples (Table 1 and 
supplementary data S1, available at Annals of Oncology online). 
None of them were recurrent mutations but, in three patients, 
we observed mutations affecting the TP53 gene (Figure 2). One 
patient contained a STOP gained mutation at amino acid 
number 192, and another patient had a nonsynonymous muta-
tion corresponding to amino acid 159 of the TP53 protein 
followed by two deletions of 3 and 13 bp that leads to a frame-
shift. A third patient carried a mutation located in the donor 
splice site of TP53 (corresponding to TP53 amino acid 307). We 
postulate that this latter mutation leads to the conservation of 
the intron, resulting in a truncated TP53 protein. Interestingly, 
in the dedifferentiated OS case, which carried MDM2 and CDK4 
ampliﬁcation, no other mutation was detected, suggesting that 
this tumor subtype is a distinct molecular entity (Figure 3).
discussion
In this study, we carried out whole-exome sequencing of 
samples from seven OS patients to try to identify new somatic 
mutations. We compared the mutational proﬁle of six conven-
tional high-grade OS, (comparing tumor and normal tissues 
from the same patient) and central dedifferentiated OS, known 
to have a simple genomic proﬁle with MDM2 ampliﬁcation. We 
then examined whether the mutational proﬁle obtained for each 
patient identiﬁed common signaling pathways or biomarkers 
that might play some role in the pathogenesis of OS. We identi-
ﬁed a total of 84 point mutations and 4 deletions related to 82 
different genes in OS samples. None of them were recurrent 
mutations, but in three patients we observed mutations affecting 
the TP53 gene (Figure 2). TP53 has already been described 
as one of the most mutated genes in OS [8]. Recently, Chen 
et al. and Perry et al. conducted whole-genome sequencing and 
whole-exome and RNA sequencing on 20 OS and 59 tumor/
normal sample pairs, respectively [6, 7] and identiﬁed p53 
pathway alterations with a high frequency of mutations mostly 
in the ﬁrst intron of the TP53 gene [8]. The TP53 gene muta-
tions found in our study were new mutations, not previously 
described in the dbSNP database. These mutations lead to a 
truncated form of TP53 with the TP53 transactivation domain
Interestingly, even in the dedifferentiated form, no point muta-
tions were found, reinforcing the idea that this subtype of OS
with MDM2 ampliﬁcation is distinct from the high-grade con-
ventional OS subtype. We also observed that the highest rate of
somatic point mutations occurred in cases (patients 5 and 6)
that did not contain alterations in the TP53 and RB1 genes.
These ﬁndings suggest that TP53mutations and, to some extent,
RB1 mutations are founding events in the process of bone onco-
genesis and that, in the absence of these mutations. a higher rate
of genetic alteration is required. Of note, patient 5 was the only
patient with a poor response to chemotherapy (27% of viable
cells) and had the highest number of mutated genes (n = 45),
suggesting poor response to chemotherapy, and so on; poor
prognosis is associated to high level of mutations. We can also
hypothesize that patients with TP 53 gene mutations may have a
better response to chemotherapy.
Collectively, in line with previously reported studies our data
suggest that OS is an extremely heterogeneous tumor with
regard to genetic alterations (Figure 3). Indeed, TP53 represents
a key gene mutated in a signiﬁcant number of cases. Of particu-
lar interest is the wide diversity of TP53 mutations, all of them
leading to inactivation of this tumor suppressor protein and
supporting chromothripsis as a critical process in bone onco-
genesis. Three main observations arise from our study: (i)
whole-exome sequencing has allowed us to identify mutated
genes that have not been previously reported in OS; (ii) dediffer-
entiated OS harboring MDM2 ampliﬁcations do not carry any
other mutations, strongly indicating that this subtype represents
a clinico-pathological entity with distinct oncogenic mechan-
isms that requires different therapeutic management (Figure 3);
(iii) TP53 (and RB1) inactivation is the strongest oncogenic
event in OS development, requiring a limited number of sec-
ondary genetic mutations (Figure 3).
These data conﬁrm that the development of targeted therapies
for OS will be difﬁcult and that in the future a personalized ap-
proach is the most realistic avenue for providing patients with
efﬁcient treatment.
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Figure 3. Mutational spectrum of osteosarcoma isolates distinct subgroups.
Note that tumors with either TP53 or RB1 mutations display relative low
number of secondary mutations compared with patients with wild-type
genes. MDM2 ampliﬁcation identiﬁes a speciﬁc subgroup of tumor devoid
of secondary mutations (dedifferentiated osteosarcoma).
